Given the high levels of both structural and functional overlap between CRB1 and CRB2, as well as the apparent need to express CRB proteins in both photoreceptors and Müller glial cells in order to maintain a functional retina, we believe that human CRB2-mediated gene therapy may represent a safe and viable treatment for fighting blindness due to mutations in CRB1. The gene discussed is CRB2; the disease is blindness (disorder).